Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Acalabrutinib (Calquence) for Chronic Lymphocytic Leukemia
(Open for Input on Submission until April 22, 2020)

Acalabrutinib (Calquence) for Chronic Lymphocytic Leukemia (previously untreated)
(Open for Input on Submission until April 22, 2020)

Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma in Combination with Doxorubicin, Vinblastine, and Dacarbazine
(Open for Input on Submission until April 17, 2020)

Brentuximab Vedotin (Adcetris) for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides
(Open for Input on Submission until April 14, 2020)

Ribociclib (Kisqali) with Fulvestrant for Advanced or Metastatic Breast Cancer
(Open for Input on Recommendation until April 17, 2020)

Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer
(Open for Input on Recommendation until April 17, 2020)

Darolutamide (Nubeqa) for Non-Metastatic Castration Resistant Prostate Cancer
(Open for Input on Recommendation until April 17, 2020)

Brentuximab Vedotin (Adcetris) for Peripheral T-Cell Lymphoma
(Open for Input on Recommendation until April 17, 2020)

Cabozantinib (Cabometyx) for Hepatocellular Carcinoma
(Open for Input on Recommendation until April 17, 2020)

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer
(Open for Input on Recommendation until April 17, 2020)

Pembrolizumab (Keytruda) for Renal Cell Carcinoma
(Final Recommendation Issued as of April 17, 2019)

Gemtuzumab Ozogamicin (Mylotarg) for Acute Myeloid Leukemia
(Final Recommendation Issued as of April 17, 2019)

Midostaurin (Rydapt) for Systemic Mastocytosis
(Final Recommendation Issued as of April 17, 2019)

Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer
(Notification to Implement Issued as of April 8, 2020)

Glasdegib (Daurismo) for Acute Myeloid Leukemia
(Pending Submission as of April 7, 2020)

Pembrolizumab (Keytruda) for Head and Neck Squamous Cell Carcinoma
(Pending Submission as of March 19, 2020)

Venetoclax (Venclexta) in Combination with Obinutuzumab for Chronic Lymphocytic Leukemia
(Pending Submission as of March 19, 2020)

Find a Drug Review